MNG1226
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PANCREAS_BETA_CELLS+0.351
- G2M_CHECKPOINT+0.299
- E2F_TARGETS+0.239
- SPERMATOGENESIS+0.169
- KRAS_SIGNALING_DN+0.105
- KRAS_SIGNALING_UP+0.031
- NOTCH_SIGNALING+0.023
- ALLOGRAFT_REJECTION+0.004
- HEDGEHOG_SIGNALING-0.002
- UV_RESPONSE_DN-0.016
Top 10 suppressed
- CHOLESTEROL_HOMEOSTASIS-0.454
- DNA_REPAIR-0.417
- UNFOLDED_PROTEIN_RESPONSE-0.414
- HYPOXIA-0.384
- ADIPOGENESIS-0.383
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.383
- MTORC1_SIGNALING-0.379
- OXIDATIVE_PHOSPHORYLATION-0.348
- GLYCOLYSIS-0.344
- PROTEIN_SECRETION-0.338
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_HHPA8NJ2 | medulloblastoma | — | 0.888 |
| 2 | SRR934972 | — | — | 0.885 |
| 3 | TCGA-DQ-7591-01A-11R-2081-07 | — | — | 0.878 |
| 4 | C3L-02616 | — | cohortMD1 | 0.876 |
| 5 | TCGA-QK-A6IF-01A-11R-A31N-07 | — | — | 0.867 |
| 6 | SRR934973 | — | — | 0.860 |
| 7 | TCGA-BA-A4IH-01A-11R-A266-07 | — | — | 0.860 |
| 8 | BS_4GTESTSE | Ganglioglioma | — | 0.857 |
| 9 | SRR934905 | — | — | 0.856 |
| 10 | TCGA-BB-4223-01A-01R-1436-07 | — | — | 0.853 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 8 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PANCREAS_BETA_CELLS | 0.351 | Cobimetinib | — uncovered |
| G2M_CHECKPOINT | 0.299 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.239 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.169 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.105 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_UP | 0.031 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.023 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.004 | Idelalisib | — uncovered |